Report #2841528

Received May 19, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Female
Age: Age unknown
State: NC
Recovered: Unknown
Vaccinated: May 2, 2025
Onset: May 2, 2025
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
VARZOS	ZOSTER (SHINGRIX)	GLAXOSMITHKLINE BIOLOGICALS	1	FJ9A7	LA

Symptoms (1)

Product preparation issue

Symptom narrative

received the diluent without the adjuvant; received the diluent without the adjuvant; This non-serious case was reported by a physician via sales rep and described the occurrence of inappropriate preparation of medication in a 54-year-old female patient who received Herpes zoster (Shingrix) (batch number FJ9A7, expiry date 16-JUL-2026) for prophylaxis. Concurrent medical conditions included cholesterol. Concomitant products included atorvastatin calcium (Lipitor). On 02-MAY-2025, the patient received the 1st dose of Shingrix (left deltoid). On 02-MAY-2025, an unknown time after receiving Shingrix, the patient experienced inappropriate preparation of medication (Verbatim: received the diluent without the adjuvant) and inappropriate dose of vaccine administered (Verbatim: received the diluent without the adjuvant). The outcome of the inappropriate preparation of medication and inappropriate dose of vaccine administered were not applicable. Additional Information: GSK Receipt Date: 09-MAY-2025 The physician reported that the patient received the diluent without the adjuvant, which led to inappropriate preparation of medication and inappropriate dose of vaccine administered.

Current illness

Cholesterol

Other medications

LIPITOR